Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Enliven Therapeutics, Inc.ELVN · Entity 4024 | CHIEF FINANCIAL OFFICER | September 17, 2026 | September 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Enliven Therapeutics, Inc.
Report date September 17, 2026 · Filed September 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,000 |
Last balance in matching sequence
After 2026-09-17 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2026-09-17 · Exercise / conversion · Acquired 3,982 · Balance 44,018 F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Row 2 · 2026-09-17 · Sale · Disposed 3,535 · Balance 40,483 F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F3: This transaction was executed in multiple trades at prices ranging from $49.31 to $50.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Row 3 · 2026-09-17 · Sale · Disposed 2,194 · Balance 38,289 F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F4: This transaction was executed in multiple trades at prices ranging from $50.31 to $51.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Row 4 · 2026-09-17 · Sale · Disposed 289 · Balance 38,000 F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F5: This transaction was executed in multiple trades at prices ranging from $51.365 to $51.70. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.85 · Expires 2034-02-13 | Direct | 181,018 |
Reported balance
After 2026-09-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-17 · Exercise / conversion · Disposed 3,982 · Balance 181,018 F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F6: The option, originally for 185,000 shares, vested as to one-fourth of the shares on February 13, 2025, and the remainder of the shares vest in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026.
F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F3: This transaction was executed in multiple trades at prices ranging from $49.31 to $50.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4: This transaction was executed in multiple trades at prices ranging from $50.31 to $51.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5: This transaction was executed in multiple trades at prices ranging from $51.365 to $51.70. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6: The option, originally for 185,000 shares, vested as to one-fourth of the shares on February 13, 2025, and the remainder of the shares vest in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 17, 2026 Filed Sep 21, 2026 21:23 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 3,982 | $0.00 Strike: $14.85 | $0.00 |
DisclosureSEC source: 0001882764-26-000008 · form4-09212026_090936.xml · derivative · entry 5 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,018 Underlying: Common Stock · 3,982 shares Expires 2034-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F6 · derivative.exercise_date: The option, originally for 185,000 shares, vested as to one-fourth of the shares on February 13, 2025, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 21:23 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 289 | $51.49 | $14,881.45 |
DisclosureSEC source: 0001882764-26-000008 · form4-09212026_090936.xml · nonDerivative · entry 4 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,000 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F5 · price: This transaction was executed in multiple trades at prices ranging from $51.365 to $51.70. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 21:23 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 2,194 | $50.72 | $111,270.47 |
DisclosureSEC source: 0001882764-26-000008 · form4-09212026_090936.xml · nonDerivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,289 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F4 · price: This transaction was executed in multiple trades at prices ranging from $50.31 to $51.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 21:23 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 3,535 | $50.03 | $176,851.10 |
DisclosureSEC source: 0001882764-26-000008 · form4-09212026_090936.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,483 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F3 · price: This transaction was executed in multiple trades at prices ranging from $49.31 to $50.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 21:23 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 3,982 | $14.85 | $59,132.70 |
DisclosureSEC source: 0001882764-26-000008 · form4-09212026_090936.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:17 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,388 | $59.35 | $82,382.80 |
DisclosureSEC source: 0001882764-26-000007 · form4-08192026_080843.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,036 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F4 · price: This transaction was executed in multiple trades at prices ranging from $58.945 to $59.60. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:17 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 4,630 | $58.35 | $270,168.37 |
DisclosureSEC source: 0001882764-26-000007 · form4-08192026_080843.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,424 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F2 · price: This transaction was executed in multiple trades at prices ranging from $57.895 to $58.89. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| July 17, 2026 Filed Jul 21, 2026 21:24 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 1,072 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001882764-26-000006 · form4-07212026_090724.xml · derivative · entry 7 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,966 Underlying: Common Stock · 1,072 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F8 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 17, 2026 Filed Jul 21, 2026 21:24 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 123 | $53.87 | $6,626.21 |
DisclosureSEC source: 0001882764-26-000006 · form4-07212026_090724.xml · nonDerivative · entry 6 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,054 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F7 · price: This transaction was executed in multiple trades at prices ranging from $53.78 to $53.9781. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| July 17, 2026 Filed Jul 21, 2026 21:24 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 2,638 | $53.38 | $140,823.04 |
DisclosureSEC source: 0001882764-26-000006 · form4-07212026_090724.xml · nonDerivative · entry 5 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,177 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F6 · price: This transaction was executed in multiple trades at prices ranging from $52.77 to $53.7685. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| July 17, 2026 Filed Jul 21, 2026 21:24 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 2,564 | $52.32 | $134,143.35 |
DisclosureSEC source: 0001882764-26-000006 · form4-07212026_090724.xml · nonDerivative · entry 4 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,815 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F5 · price: This transaction was executed in multiple trades at prices ranging from $51.77 to $52.7695. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| July 17, 2026 Filed Jul 21, 2026 21:24 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 369 | $51.48 | $18,996.97 |
DisclosureSEC source: 0001882764-26-000006 · form4-07212026_090724.xml · nonDerivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,379 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F4 · price: This transaction was executed in multiple trades at prices ranging from $50.765 to $51.7481. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| July 17, 2026 Filed Jul 21, 2026 21:24 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 324 | $49.97 | $16,190.77 |
DisclosureSEC source: 0001882764-26-000006 · form4-07212026_090724.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,748 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F3 · price: This transaction was executed in multiple trades at prices ranging from $49.72 to $50.3778. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| July 17, 2026 Filed Jul 21, 2026 21:24 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 1,072 | $2.48 | $2,658.56 |
DisclosureSEC source: 0001882764-26-000006 · form4-07212026_090724.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,072 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 21:13 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 6,018 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001882764-26-000005 · form4-06222026_090607.xml · derivative · entry 5 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,038 Underlying: Common Stock · 6,018 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F6 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 21:13 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,238 | $44.75 | $55,397.41 |
DisclosureSEC source: 0001882764-26-000005 · form4-06222026_090607.xml · nonDerivative · entry 4 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,000 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F5 · price: This transaction was executed in multiple trades at prices ranging from $44.3548 to $44.945. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 21:13 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 3,401 | $43.86 | $149,179.42 |
DisclosureSEC source: 0001882764-26-000005 · form4-06222026_090607.xml · nonDerivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,238 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F4 · price: This transaction was executed in multiple trades at prices ranging from $43.3342 to $44.3142. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 21:13 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,379 | $42.79 | $59,000.52 |
DisclosureSEC source: 0001882764-26-000005 · form4-06222026_090607.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,639 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F3 · price: This transaction was executed in multiple trades at prices ranging from $42.295 to $43.27. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 21:13 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 6,018 | $2.48 | $14,924.64 |
DisclosureSEC source: 0001882764-26-000005 · form4-06222026_090607.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 22:15 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 10,000 | $29.58 | $295,839.00 |
DisclosureSEC source: 0001882764-26-000002 · form4-03102026_100318.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,000 F1 · price: This transaction was executed in multiple trades at prices ranging from $29.43 to $29.7867. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2 · balance_after: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:49 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $27.16 | $0.00 |
DisclosureSEC source: 0001882764-26-000001 · form4-02182026_120228.xml · derivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2036-02-12 F3 · derivative.exercise_date: 1/4th of the shares subject to the option will vest on February 12, 2027 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:49 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001882764-26-000001 · form4-02182026_120228.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,000 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date. F2 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 23:47 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 13,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001882764-25-000005 · form4-12232025_111212.xml · derivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,056 Underlying: Common Stock · 13,000 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 23:47 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 13,000 | $2.48 | $32,240.00 |
DisclosureSEC source: 0001882764-25-000005 · form4-12232025_111212.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 29, 2025 Filed Oct 1, 2025 20:46 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 3,250 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001882764-25-000004 · form4-10012025_081027.xml · derivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,056 Underlying: Common Stock · 3,250 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| September 29, 2025 Filed Oct 1, 2025 20:46 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 3,250 | $20.40 | $66,291.23 |
DisclosureSEC source: 0001882764-25-000004 · form4-10012025_081027.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,000 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.025 to $20.71. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 29, 2025 Filed Oct 1, 2025 20:46 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 3,250 | $2.48 | $8,060.00 |
DisclosureSEC source: 0001882764-25-000004 · form4-10012025_081027.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| August 27, 2025 Filed Aug 29, 2025 21:03 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 3,250 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-25-023310 · form4-08292025_090813.xml · derivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,306 Underlying: Common Stock · 3,250 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 27, 2025 Filed Aug 29, 2025 21:03 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 3,250 | $20.63 | $67,038.73 |
DisclosureSEC source: 0001415889-25-023310 · form4-08292025_090813.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,000 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.27 to $20.8689. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 27, 2025 Filed Aug 29, 2025 21:03 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 3,250 | $2.48 | $8,060.00 |
DisclosureSEC source: 0001415889-25-023310 · form4-08292025_090813.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| July 28, 2025 Filed Jul 30, 2025 21:57 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 3,250 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-25-020605 · form4-07302025_090748.xml · derivative · entry 4 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,556 Underlying: Common Stock · 3,250 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 28, 2025 Filed Jul 30, 2025 21:57 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 65 | $21.30 | $1,384.52 |
DisclosureSEC source: 0001415889-25-020605 · form4-07302025_090748.xml · nonDerivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,000 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $21.1377 to $21.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 28, 2025 Filed Jul 30, 2025 21:57 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 3,185 | $20.45 | $65,119.24 |
DisclosureSEC source: 0001415889-25-020605 · form4-07302025_090748.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,065 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.09 to $21.08. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 28, 2025 Filed Jul 30, 2025 21:57 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 3,250 | $2.48 | $8,060.00 |
DisclosureSEC source: 0001415889-25-020605 · form4-07302025_090748.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| July 10, 2025 Filed Jul 14, 2025 21:07 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-25-019730 · form4-07142025_090730.xml · derivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,806 Underlying: Common Stock · 1,000 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 10, 2025 Filed Jul 14, 2025 21:07 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,000 | $22.66 | $22,655.00 |
DisclosureSEC source: 0001415889-25-019730 · form4-07142025_090730.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,000 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.59 to $22.72. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 10, 2025 Filed Jul 14, 2025 21:07 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 1,000 | $2.48 | $2,480.00 |
DisclosureSEC source: 0001415889-25-019730 · form4-07142025_090730.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| June 27, 2025 Filed Jul 1, 2025 20:42 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 3,250 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-25-018718 · form4-07012025_080730.xml · derivative · entry 4 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,806 Underlying: Common Stock · 3,250 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| June 27, 2025 Filed Jul 1, 2025 20:42 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 198 | $21.66 | $4,288.34 |
DisclosureSEC source: 0001415889-25-018718 · form4-07012025_080730.xml · nonDerivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,000 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $21.5811 to $21.788. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 27, 2025 Filed Jul 1, 2025 20:42 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 3,052 | $20.86 | $63,667.47 |
DisclosureSEC source: 0001415889-25-018718 · form4-07012025_080730.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,198 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.58 to $21.575. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 27, 2025 Filed Jul 1, 2025 20:42 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 3,250 | $2.48 | $8,060.00 |
DisclosureSEC source: 0001415889-25-018718 · form4-07012025_080730.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 20:24 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-25-017532 · form4-06172025_080605.xml · derivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,056 Underlying: Common Stock · 3,000 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 20:24 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 3,000 | $22.55 | $67,655.40 |
DisclosureSEC source: 0001415889-25-017532 · form4-06172025_080605.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,000 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.50 to $22.56. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 20:24 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 3,000 | $2.48 | $7,440.00 |
DisclosureSEC source: 0001415889-25-017532 · form4-06172025_080605.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| May 27, 2025 Filed May 29, 2025 21:38 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 3,250 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-25-014913 · form4-05292025_090525.xml · derivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,056 Underlying: Common Stock · 3,250 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| May 27, 2025 Filed May 29, 2025 21:38 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 3,250 | $16.18 | $52,593.45 |
DisclosureSEC source: 0001415889-25-014913 · form4-05292025_090525.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,000 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.925 to $16.675. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 27, 2025 Filed May 29, 2025 21:38 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 3,250 | $2.48 | $8,060.00 |
DisclosureSEC source: 0001415889-25-014913 · form4-05292025_090525.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| April 28, 2025 Filed Apr 30, 2025 22:59 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 3,250 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-25-011596 · form4-04302025_100450.xml · derivative · entry 4 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,306 Underlying: Common Stock · 3,250 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| April 28, 2025 Filed Apr 30, 2025 22:59 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 69 | $19.12 | $1,319.02 |
DisclosureSEC source: 0001415889-25-011596 · form4-04302025_100450.xml · nonDerivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,000 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $19.1111 to $19.1218. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 28, 2025 Filed Apr 30, 2025 22:59 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 3,181 | $18.68 | $59,418.54 |
DisclosureSEC source: 0001415889-25-011596 · form4-04302025_100450.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,069 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $18.09 to $19.0724. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.